Media Kits
Cyramza® (ramucirumab) Approved by the U.S. FDA as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Read More About Cyramza
Retevmo™ (selpercatinib): First Therapy Specifically for Patients with Advanced RET-Driven Cancers Is Approved
Read More About Retevmo
Reyvow™ (lasmiditan) C-V: A First-in-Class Acute Treatment for Migraine Is Now Available
Read More About Reyvow